Table 3 Identification of key MMD-associated target genes
From: Immune response profiling identifies autoantibodies specific to Moyamoya patients
Proteins | Enriched p value | Function | ProtoArray p value | DER * | Chromosomal location |
|---|---|---|---|---|---|
APP | < 0.02 | Increased risk of hemorrhagic stroke, Alzheimer disease pathogenesis, DDR [40–42] | 0.029 | 0.604 | 21q21.3 |
CTNNB1 | 0.01 | Regulation of neural progenitor cell cycle, Wnt signaling in carcinoma/angiogenesis, chromosome instability [43–45] | 0.0197 | 0.555 | 3p21 |
EDIL3 | 0.01 | Role in angiogenesis and vessel wall remodeling and development [46, 47] | 0.0003 | 0.484 | 5q14 |
ROR1 | 0.01 | Possible role in cell migration and remodeling of cytoskeleton [48] | 0.0029 | 0.586 | 1p32-p31 |
GPS1 | 0.02 | Component of the COP9 signalosome, DDR [49] | 0.07 | 0.46 | 17q25.3 |
STRA13 | 0.01 | Component of the FA protein complex, DDR, component of the kinetocore [50–52] | 0.0021 | 0.581 | 17q25.3 |